The Market Reports

Synopsis
The global market for Gene Therapy On Cardiovascular Disease was estimated to be worth US$ 322 million in 2024 and is forecast to a readjusted size of US$ 28430 million by 2031 with a CAGR of 91.0% during the forecast period 2025-2031.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
Market Driver: The increasing prevalence of cardiovascular diseases (CVDs) worldwide is a major driver for the gene therapy market in this area. As traditional treatments, such as surgery, medications, and lifestyle changes, sometimes fail to offer long-term solutions, gene therapy presents a promising alternative. By targeting the root causes of CVDs at the genetic level, gene therapy offers the potential for more effective and durable treatments. Advancements in gene editing technologies, such as CRISPR, have further accelerated the development of gene therapies for cardiovascular diseases, allowing for precise modification of genes that regulate heart function, blood vessel health, and inflammation. This technological progress, combined with the growing demand for personalized and innovative treatments, is driving the market forward.Market Challenge: Despite its potential, the gene therapy market for cardiovascular diseases faces several challenges, including high development costs and the complexity of clinical trials. Developing safe and effective gene therapies requires significant investment in research and long-term testing, which can delay the availability of these therapies to patients. Additionally, regulatory approval for gene therapies can be slow and uncertain, creating barriers to rapid commercialization. Moreover, there are concerns regarding the long-term safety and potential unintended genetic consequences of modifying human DNA, which may limit widespread adoption. The complexity of delivering gene therapies to the cardiovascular system, such as targeting specific cells or tissues without causing adverse effects, remains a significant technical challenge.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy On Cardiovascular Disease, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gene Therapy On Cardiovascular Disease by region & country, by Type, and by Application.
The Gene Therapy On Cardiovascular Disease market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy On Cardiovascular Disease.
Market Segmentation
By Company
Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis
Biogen
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy
Segment by Application
Heart Disease
Vascular Disease
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gene Therapy On Cardiovascular Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Gene Therapy On Cardiovascular Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Gene Therapy On Cardiovascular Disease in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index